AI Engines For more Details: Perplexity Kagi Labs You
Sedation: Glutethimide exerts its primary effect as a central nervous system depressant, leading to sedation and drowsiness. It was historically used as a sleep aid due to its sedative properties.
Hypnotic Effects: Glutethimide has hypnotic effects, meaning it can induce sleep and promote relaxation. However, its use for this purpose has declined due to concerns about safety and the risk of dependence.
Muscle Relaxation: Glutethimide also possesses muscle relaxant properties, which can contribute to its sedative effects. It was sometimes prescribed for conditions involving muscle spasms or tension.
Anticonvulsant Properties: In addition to its sedative and muscle relaxant effects, glutethimide has been found to exhibit anticonvulsant properties. However, its use for this purpose is limited due to safety concerns and the availability of safer anticonvulsant medications.
Addiction and Dependence: Glutethimide has a high potential for addiction and dependence, especially when used for an extended period or in high doses. Chronic use of glutethimide can lead to tolerance, dependence, and withdrawal symptoms upon discontinuation.
Respiratory Depression: Like other sedative-hypnotic drugs, glutethimide can cause respiratory depression, particularly when taken in high doses or in combination with other central nervous system depressants such as alcohol or opioids. Severe respiratory depression can be life-threatening.
Overdose: Glutethimide overdose can result in severe central nervous system depression, coma, and death. Overdose requires immediate medical attention and supportive care, including airway management and administration of antidotes if available.
Drug Interactions: Glutethimide can interact with other medications, including other central nervous system depressants, leading to additive effects and increasing the risk of respiratory depression, sedation, and overdose.
Withdrawal Syndrome: Abrupt discontinuation of glutethimide after long-term use can result in withdrawal symptoms, including rebound insomnia, anxiety, agitation, tremors, and seizures. Withdrawal should be managed under medical supervision to minimize the risk of complications.
Regulatory Status: Due to its high potential for abuse, addiction, and overdose, glutethimide is a controlled substance in many countries. Its use is restricted, and it is not commonly prescribed in clinical practice.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 0.9 | 0.3 | 2 |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.5 | 0.8 |
| Allergies | 1.4 | 0.7 | 1 |
| Allergy to milk products | 0.8 | 0.6 | 0.33 |
| Alzheimer's disease | 1.4 | 1.5 | -0.07 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.5 | 0.8 |
| Ankylosing spondylitis | 1.1 | 0.6 | 0.83 |
| Anorexia Nervosa | 0.6 | 0.6 | 0 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 1.1 | 0.3 | 2.67 |
| Atherosclerosis | 0.8 | 0 | 0 |
| Atrial fibrillation | 0.9 | 0.6 | 0.5 |
| Autism | 1.8 | 2 | -0.11 |
| Autoimmune Disease | 0.9 | 0.9 | |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.6 | |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 0.9 | 0.6 | 0.5 |
| Brain Trauma | 0.3 | 0.3 | 0 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.3 | 0.1 | 2 |
| Carcinoma | 1.7 | 0.3 | 4.67 |
| Celiac Disease | 0.5 | 0.3 | 0.67 |
| Cerebral Palsy | 0.3 | 0.3 | 0 |
| Chronic Fatigue Syndrome | 1.2 | 1 | 0.2 |
| Chronic Kidney Disease | 0.6 | 0.3 | 1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 0.9 | 0.56 |
| Chronic Urticaria (Hives) | 1.1 | 1.1 | |
| Coagulation / Micro clot triggering bacteria | 1.1 | 0.6 | 0.83 |
| Cognitive Function | 0.6 | 0.3 | 1 |
| Colorectal Cancer | 2.6 | 0.5 | 4.2 |
| Constipation | 0.9 | 0.9 | |
| Coronary artery disease | 1.4 | 0.3 | 3.67 |
| COVID-19 | 1.7 | 1.4 | 0.21 |
| Crohn's Disease | 2.3 | 0.9 | 1.56 |
| Cushing's Syndrome (hypercortisolism) | 0 | 0 | |
| cystic fibrosis | 0.8 | 0.8 | |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 1.6 | 0.6 | 1.67 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 2.1 | 1.6 | 0.31 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.2 | 0.6 | 1 |
| Endometriosis | 1.4 | 0.8 | 0.75 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 1.4 | 1.4 | |
| erectile dysfunction | 0.9 | 0.9 | |
| Fibromyalgia | 0.1 | -0.1 | |
| Functional constipation / chronic idiopathic constipation | 1.7 | 0.6 | 1.83 |
| gallstone disease (gsd) | 1.1 | 0.3 | 2.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.6 | 0.3 | 1 |
| Generalized anxiety disorder | 1.7 | 0.6 | 1.83 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | 0 |
| Graves' disease | 0.3 | 0.9 | -2 |
| Gulf War Syndrome | 0.6 | 0.6 | |
| Halitosis | 0.8 | 0.3 | 1.67 |
| Hashimoto's thyroiditis | 0.6 | 0.6 | |
| Heart Failure | 1.9 | 0.3 | 5.33 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.2 | 0.3 | -0.5 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
| hyperglycemia | 1.1 | 1.1 | |
| hypertension (High Blood Pressure | 1.2 | 0.9 | 0.33 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.8 | 0.8 | |
| IgA nephropathy (IgAN) | 0.9 | 0.9 | |
| Inflammatory Bowel Disease | 2 | 1.5 | 0.33 |
| Insomnia | 0.9 | 0.6 | 0.5 |
| Intelligence | 0.5 | 0.5 | |
| Intracranial aneurysms | 0.6 | 0.3 | 1 |
| Irritable Bowel Syndrome | 1.6 | 0.9 | 0.78 |
| ischemic stroke | 0.8 | 0.6 | 0.33 |
| Liver Cirrhosis | 2.3 | 1.4 | 0.64 |
| Long COVID | 1.3 | 1 | 0.3 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.6 | 0.3 | 1 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.1 | 0.6 | 0.83 |
| ME/CFS with IBS | 0.3 | 0.1 | 2 |
| ME/CFS without IBS | 0.3 | 0.3 | |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 2 | 1.2 | 0.67 |
| Mood Disorders | 1.8 | 1.6 | 0.13 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.6 | |
| Multiple Sclerosis | 1.9 | 0.9 | 1.11 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0.9 | 0.9 | |
| Neuropathy (all types) | 0.3 | 0.6 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.7 | 0.6 | 1.83 |
| Obesity | 2 | 1.8 | 0.11 |
| obsessive-compulsive disorder | 1.2 | 0.6 | 1 |
| Osteoarthritis | 0.9 | 0.6 | 0.5 |
| Osteoporosis | 0.9 | 0.3 | 2 |
| pancreatic cancer | 0.5 | 0.3 | 0.67 |
| Parkinson's Disease | 1.8 | 1.8 | 0 |
| Polycystic ovary syndrome | 1.9 | 0.7 | 1.71 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 0.6 | 0.6 | 0 |
| Psoriasis | 0.8 | 0.3 | 1.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 0.6 | 2 |
| Rosacea | 0.3 | 0.3 | |
| Schizophrenia | 1.2 | 0.6 | 1 |
| scoliosis | 0.5 | 0.3 | 0.67 |
| Sjögren syndrome | 0.9 | 0.9 | |
| Sleep Apnea | 0.9 | 0.6 | 0.5 |
| Slow gastric motility / Gastroparesis | 0.5 | 0.5 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 1.1 | |
| Stress / posttraumatic stress disorder | 0.5 | 0.3 | 0.67 |
| Systemic Lupus Erythematosus | 1.5 | 0.3 | 4 |
| Tic Disorder | 0.6 | 0.6 | |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 1.5 | 0.6 | 1.5 |
| Type 2 Diabetes | 2.3 | 1.4 | 0.64 |
| Ulcerative colitis | 1.4 | 0.6 | 1.33 |
| Unhealthy Ageing | 1.2 | 0.3 | 3 |
| Vitiligo | 0.6 | 0.1 | 5 |
